FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024557546> ?p ?o ?g. }

• W2024557546 endingPage "118" @default.
• W2024557546 startingPage "118" @default.
• W2024557546 abstract "Introduction: We evaluate the efficacy and safety of solifenacin to treat incontinence in children with non-neurogenic (DO) or neurogenic detrusor overactivity (NDO) refractory to oxybutininor tolterodine.Methods: We updated and extended our previously published non-randomized uncontrolled study on open-label use of adjusted-dose regimens of solifenacin (1.25-10 mg) in children with refractory incontinence. The follow-up included voiding diaries, post-void residuals, urine cultures, ultrasounds and urodynamic studies. Clinical data were updated as of September 2012. Subjective improvement was assessed with the Patient Perception of Bladder Condition (PPBC) scale. The primary end point was efficacy toward continence and secondary end points were tolerability and safety.Results: Overall, 244 patients (112 girls, 132 boys) were enrolled; 53 with NDO and 191 with DO. Minimal follow-up was 5 months, the mean duration of treatment was 21.0 months and the mean age at initiation was 9.2 years. Urodynamic capacity improved from 145 ± 76 mL to 339 ± 152 mL and the amplitude of uninhibited contractions decreased from 66 ± 26 to 20 ± 20 cmH2O (p < 0.0001). The overall success rate is 91%, and more specifically 94% for non-neurogenic and 79% for neurogenic, which is significantly different (p = 0.013). Twenty-three patients discontinued treatment for unsatisfactory clinical response or bothersome side effects. No side effects were reported by 175 patients, mild by 46, moderate by 9, and 14 withdrew due to their side effects. Ten patients developed post-void residuals of ≥20 mL.Conclusion: Although higher in the non-neurogenic group, high subjective and objective success rates were maintained over a longer follow-up with an adjusted-dose regimen of solifenacin to treat pediatric NDO or DO refractory to oxybutynin or tolterodine. Moreover, we found acceptable tolerability and safety profiles." @default.
• W2024557546 created "2016-06-24" @default.
• W2024557546 creator A5008361474 @default.
• W2024557546 creator A5016617932 @default.
• W2024557546 creator A5017520094 @default.
• W2024557546 creator A5023759717 @default.
• W2024557546 creator A5043201110 @default.
• W2024557546 creator A5050032986 @default.
• W2024557546 creator A5062793982 @default.
• W2024557546 creator A5083936150 @default.
• W2024557546 date "2014-04-14" @default.
• W2024557546 modified "2023-10-03" @default.
• W2024557546 title "Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study" @default.
• W2024557546 cites W1964781318 @default.
• W2024557546 cites W1969740456 @default.
• W2024557546 cites W1969763715 @default.
• W2024557546 cites W1981218720 @default.
• W2024557546 cites W1998003688 @default.
• W2024557546 cites W2009822389 @default.
• W2024557546 cites W2013378474 @default.
• W2024557546 cites W2028950772 @default.
• W2024557546 cites W2054785014 @default.
• W2024557546 cites W2054938611 @default.
• W2024557546 cites W2080512255 @default.
• W2024557546 cites W2080534713 @default.
• W2024557546 cites W2085107167 @default.
• W2024557546 cites W2086911242 @default.
• W2024557546 cites W2095018779 @default.
• W2024557546 cites W2095861126 @default.
• W2024557546 cites W2116324813 @default.
• W2024557546 cites W2120812596 @default.
• W2024557546 cites W2135164423 @default.
• W2024557546 doi "https://doi.org/10.5489/cuaj.1356" @default.
• W2024557546 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4001633" @default.
• W2024557546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24839481" @default.
• W2024557546 hasPublicationYear "2014" @default.
• W2024557546 type Work @default.
• W2024557546 sameAs 2024557546 @default.
• W2024557546 citedByCount "30" @default.
• W2024557546 countsByYear W20245575462014 @default.
• W2024557546 countsByYear W20245575462015 @default.
• W2024557546 countsByYear W20245575462016 @default.
• W2024557546 countsByYear W20245575462017 @default.
• W2024557546 countsByYear W20245575462018 @default.
• W2024557546 countsByYear W20245575462019 @default.
• W2024557546 countsByYear W20245575462020 @default.
• W2024557546 countsByYear W20245575462021 @default.
• W2024557546 countsByYear W20245575462022 @default.
• W2024557546 countsByYear W20245575462023 @default.
• W2024557546 crossrefType "journal-article" @default.
• W2024557546 hasAuthorship W2024557546A5008361474 @default.
• W2024557546 hasAuthorship W2024557546A5016617932 @default.
• W2024557546 hasAuthorship W2024557546A5017520094 @default.
• W2024557546 hasAuthorship W2024557546A5023759717 @default.
• W2024557546 hasAuthorship W2024557546A5043201110 @default.
• W2024557546 hasAuthorship W2024557546A5050032986 @default.
• W2024557546 hasAuthorship W2024557546A5062793982 @default.
• W2024557546 hasAuthorship W2024557546A5083936150 @default.
• W2024557546 hasBestOaLocation W20245575461 @default.
• W2024557546 hasConcept C121332964 @default.
• W2024557546 hasConcept C126322002 @default.
• W2024557546 hasConcept C126894567 @default.
• W2024557546 hasConcept C142424586 @default.
• W2024557546 hasConcept C142724271 @default.
• W2024557546 hasConcept C188816634 @default.
• W2024557546 hasConcept C197934379 @default.
• W2024557546 hasConcept C203092338 @default.
• W2024557546 hasConcept C204787440 @default.
• W2024557546 hasConcept C2778375690 @default.
• W2024557546 hasConcept C2778531004 @default.
• W2024557546 hasConcept C2778941218 @default.
• W2024557546 hasConcept C2779502394 @default.
• W2024557546 hasConcept C2781020410 @default.
• W2024557546 hasConcept C535046627 @default.
• W2024557546 hasConcept C71924100 @default.
• W2024557546 hasConcept C87355193 @default.
• W2024557546 hasConceptScore W2024557546C121332964 @default.
• W2024557546 hasConceptScore W2024557546C126322002 @default.
• W2024557546 hasConceptScore W2024557546C126894567 @default.
• W2024557546 hasConceptScore W2024557546C142424586 @default.
• W2024557546 hasConceptScore W2024557546C142724271 @default.
• W2024557546 hasConceptScore W2024557546C188816634 @default.
• W2024557546 hasConceptScore W2024557546C197934379 @default.
• W2024557546 hasConceptScore W2024557546C203092338 @default.
• W2024557546 hasConceptScore W2024557546C204787440 @default.
• W2024557546 hasConceptScore W2024557546C2778375690 @default.
• W2024557546 hasConceptScore W2024557546C2778531004 @default.
• W2024557546 hasConceptScore W2024557546C2778941218 @default.
• W2024557546 hasConceptScore W2024557546C2779502394 @default.
• W2024557546 hasConceptScore W2024557546C2781020410 @default.
• W2024557546 hasConceptScore W2024557546C535046627 @default.
• W2024557546 hasConceptScore W2024557546C71924100 @default.
• W2024557546 hasConceptScore W2024557546C87355193 @default.
• W2024557546 hasIssue "3-4" @default.
• W2024557546 hasLocation W20245575461 @default.
• W2024557546 hasLocation W20245575462 @default.
• W2024557546 hasLocation W20245575463 @default.
• W2024557546 hasLocation W20245575464 @default.

• next